Protea, Agilent Launch Collaboration
News Dec 12, 2015
Protea Biosciences Group, Inc. has announced that it is collaborating with Agilent Technologies, Inc., to address customer challenges within existing Biopharma bioanalytical workflows in order to meet the emerging needs of the growing biopharmaceutical industry.
Under Terms of the Agreement, a Memorandum of Understanding (MOU), Protea, using Agilent instrumentation combined with its technology, will develop workflows that focus on developing new methods for the field of metabolomics.
“The field of biotherapeutics is advancing rapidly, and is in need of new, innovative solutions that identify changes in the ‘metabolic profiles’ of cells due to disease processes and drug interactions,” stated Greg Kilby, PhD., Protea’s Vice President & Chief Operating Officer.
He added, “To accelerate the pace of drug development, we need to know how a new drug interacts with the body as a whole - as completely and as early in the drug development process as possible. We believe new metabolomics workflows, including use of our LAESI mass spec imaging technology, will help address the challenges of the ballooning costs and widespread failures endemic to the drug development processes today.”
“To meet the needs of the biopharmaceutical industry, Agilent looks forward to working with Protea to develop mass spectrometry based solutions across a wide range of biopharm applications, including innovative solutions for metabolomics,” commented Tiffani Manolis, Agilent’s Biopharm/Pharm Marketing Manager.
Metabolites are the molecular products of living cells. All cells produce them, and they are essential to all bodily functions. A cell’s metabolic profile can change due to health, nutrition or environmental factors.
Metabolomics represents the goal to identify all the thousands of metabolites being produced by specific cells, and to identify changes that take place in the “metabolic profiles” of cells due to disease processes and drug interactions.
Metabolomics also is being used to improve cellular processes that support high production and quality of recombinant protein in biopharmaceutical manufacturing.
Nonalcoholic fatty liver disease produces no noticeable symptoms, but one out of every five people with it will go on to develop a more serious conditions such as nonalcoholic steatohepatosis and cirrhosis. Three new studies investigate how mitochondrial energy production is altered by the progress of fatty liver disease.READ MORE